Altoida, Inc.

Today, we reflect on the profound legacy of Dr. Martin Luther King Jr., a leader who championed equality, justice, and the power of community. His vision reminds us of the importance of working together to create a world where every individual has the opportunity to thrive. At Altoida, we are inspired by his belief in the transformative power of innovation and collaboration. As we work to advance Alzheimer’s diagnosis and care, we are driven by a shared commitment to improving the lives of others and breaking barriers in healthcare access. Today, let’s honor his legacy by continuing to strive for a brighter, more equitable future for all. #MLKDay #Equality #InnovationForGood #Healthcare

A recap from Emmanuel Streel, our Senior Director of Medical Affairs, on an event hosted by Alzheimer's Disease International. Insights like 'We need a brain span that matches our lifespan' remind us why advancing Alzheimer’s diagnostics and care is so critical. Great to see leaders like Jeff Cummings and our advisory board member, John Harrison sharing their expertise!

Our Senior Director of Medical Affairs, Emmanuel Streel, PhD represented Altoida at the Innovator’s Pitch Challenge (IPC) at RESI London this week! This global gathering of industry and investors provided an opportunity to showcase our work in Alzheimer’s diagnostics, share insights, and foster innovative collaborations in neurodegenerative disease care. We’re dedicated our mission of advancing early detection through our NeuroMarker Platform, designed to combine machine learning and augmented reality to deliver fast, objective cognitive insights for earlier intervention. Thank you to the RESI community and Life Science Nation for the opportunity to highlight our mission! #RESILondon #Altoida #AlzheimersResearch #NeuroTech #DigitalHealth #HealthcareInnovation

Alzheimer’s care is evolving, driven by groundbreaking advancements in blood biomarkers and digital tools that enable earlier, more precise diagnoses. In our latest blog, we explore innovations like the Amyloid Probability Score 2 (APS2) and how integrating blood-based biomarkers with digital cognitive assessments is transforming the diagnostic journey. These cutting-edge solutions empower clinicians to detect Alzheimer’s earlier, streamline workflows, and deliver personalized care—offering hope for improved outcomes for patients and their caregivers. Discover how these scalable, accessible innovations are shaping the future of Alzheimer’s care: https://lnkd.in/gzk37kJY #AlzheimersResearch #DigitalHealth #EarlyDetection #NeuroTech #CognitiveHealth #HealthcareInnovation #Altoida

This Thanksgiving, we want to express our heartfelt gratitude to everyone working to improve the lives of those impacted by neurological disorders like Alzheimer’s. We are deeply thankful for our partners who are tirelessly developing treatments, and for the healthcare providers and caregivers who dedicate themselves to supporting millions of patients and families around the world. To our incredible team at Altoida—your passion and innovation are at the core of our mission to advance cognitive health diagnostics. Your collaboration and dedication inspire us every day as we strive to create meaningful change. Wishing all of you—our team, partners, and supporters—a wonderful Thanksgiving filled with gratitude and hope. #Thanksgiving #Gratitude #CognitiveHealth #HealthcareInnovation #Alzheimers #Altoida

We’re thrilled to celebrate M. Florencia Iulita, PhD, for being named one of Fierce Pharma’s 2024 Fiercest Women in Life Sciences! This recognition highlights her outstanding contributions to advancing research in neurodegenerative diseases and her leadership in driving innovation at Altoida. At Altoida, we’re proud to have leaders like Florencia, whose dedication to improving early detection and care for Alzheimer’s and other neurological diseases inspires us all. Join us in congratulating her on this well-deserved honor! https://lnkd.in/gciripAB #FiercestWomen #Altoida #LifeSciences #HealthcareInnovation #NeuroTech

We had an incredible time at the CNS Summit, where our CEO, Marc Jones, joined industry leaders in clinical development and innovation. We presented a poster that highlights how our NeuroMarker Platform is designed to leverage augmented reality and machine learning to enable early detection of MCI and Alzheimer’s disease. #CNSSummit2024 #Altoida #NeuroTech #AlzheimersResearch #DigitalHealth #EarlyDetection #CognitiveHealth

We couldn’t agree more! The EMA's recommendation for Lecanemab is indeed a landmark moment, reflecting the unwavering commitment of scientists and innovators in the Alzheimer’s field. Advancements like this bring us closer to a future where patients and families have more hope and access to effective treatments. Altoida, Inc. is proud to work with the scientific community to continue to push boundaries and light the way forward.

We couldn’t agree more! The EMA's recommendation for Lecanemab is indeed a landmark moment, reflecting the unwavering commitment of scientists and innovators in the Alzheimer’s field. Advancements like this bring us closer to a future where patients and families have more hope and access to effective treatments. Altoida, Inc. is proud to work with the scientific community to continue to push boundaries and light the way forward.

?????? NEW resource alert! Today, during a public launch event, DATAcc by DiMe unveiled new Core Digital Measures of Alzheimer’s disease (ADRD) and related dementias and resources to accelerate research and care. ADRD presents one of the most complex and pressing challenges in healthcare today. With 95% of individuals affected by #ADRD also managing chronic comorbidities, the burden of care is immense—not only for healthcare systems but also for the over 16 million family members and friends who serve as caregivers. This increasing complexity in care demands better, more inclusive research, yet current data lacks diversity, particularly among Hispanic and non-white populations, leaving critical gaps in understanding how different communities experience and respond to #dementia treatments. DATAcc’s globally acceptable set of core ADRD measures will transform the focus of digital measure development efforts in ADRD, preventing disparate and siloed efforts that limit progress, instead supporting directed innovation and competition that places the patient voice at the heart of access to novel treatments development in ADRD and fuels progress in treating the heterogeneity of these complex diseases. They will: ?? Give researchers and practitioners a standardized approach to patient-centric digital measurement ?? Provide practitioners with the tools they need to monitor and engage with people with ADRD about the aspects of ADRD that matter most to them and their care partners In addition to the new core digital measures set and resources, additional ADRD digital measurement products have been added to the Library of Digital Measurement Products! ?? The new resources are available now - access them here! https://bit.ly/3O6lUQE! AbbVie Alzheimer's Drug Discovery Foundation Altoida, Inc. Aural Analytics Biogen BioSensics Boston University Cambridge Cognition Cogniant Cognito Therapeutics, Inc. Cogstate Cumulus Eisai US ki:elements Koneksa Eli Lilly and Company Linus Health Luca Healthcare Medidata Solutions Merck Oregon Health & Science University Foundation Roche Sage Bionetworks VivoSense, Inc. Winterlight Labs